Calithera Biosciences, Inc. (CALA): Price and Financial Metrics
GET POWR RATINGS... FREE!
CALA POWR Grades
- Sentiment is the dimension where CALA ranks best; there it ranks ahead of 91.32% of US stocks.
- CALA's strongest trending metric is Value; it's been moving up over the last 179 days.
- CALA's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).
CALA Stock Summary
- With a year-over-year growth in debt of -61.93%, Calithera Biosciences Inc's debt growth rate surpasses only 5.1% of about US stocks.
- Revenue growth over the past 12 months for Calithera Biosciences Inc comes in at 225%, a number that bests 96.41% of the US stocks we're tracking.
- The volatility of Calithera Biosciences Inc's share price is greater than that of 98.56% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to Calithera Biosciences Inc, a group of peers worth examining would be MRUS, APTX, CRUS, XBIT, and KLDO.
- Visit CALA's SEC page to see the company's official filings. To visit the company's web site, go to www.calithera.com.
CALA Valuation Summary
- In comparison to the median Healthcare stock, CALA's price/sales ratio is 1492.11% higher, now standing at 60.5.
- CALA's price/sales ratio has moved NA NA over the prior 84 months.
- CALA's price/earnings ratio has moved up 9.8 over the prior 84 months.
Below are key valuation metrics over time for CALA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CALA | 2021-08-31 | 60.5 | 2.2 | -2.3 | -1.1 |
| CALA | 2021-08-30 | 58.3 | 2.1 | -2.2 | -1.1 |
| CALA | 2021-08-27 | 59.3 | 2.1 | -2.2 | -1.1 |
| CALA | 2021-08-26 | 58.8 | 2.1 | -2.2 | -1.1 |
| CALA | 2021-08-25 | 57.6 | 2.1 | -2.2 | -1.0 |
| CALA | 2021-08-24 | 55.8 | 2.0 | -2.1 | -1.0 |
CALA Growth Metrics
- Its 4 year cash and equivalents growth rate is now at 234.97%.
- Its year over year price growth rate is now at -70.91%.
- Its 3 year net income to common stockholders growth rate is now at -89.45%.
The table below shows CALA's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-09-30 | 9.75 | -63.729 | -68.444 |
| 2021-06-30 | 3 | -72.425 | -80.006 |
| 2021-03-31 | 0 | -79.299 | -86.086 |
| 2020-12-31 | 0 | -84.312 | -90.137 |
| 2020-09-30 | 0 | -79.706 | -89.299 |
| 2020-06-30 | 0 | -83.081 | -86.858 |
CALA's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CALA has a Quality Grade of C, ranking ahead of 50.42% of graded US stocks.
- CALA's asset turnover comes in at 0.025 -- ranking 362nd of 681 Pharmaceutical Products stocks.
- BDSI, ACOR, and INSM are the stocks whose asset turnover ratios are most correlated with CALA.
The table below shows CALA's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.025 | 1 | -32.536 |
| 2021-03-31 | 0.000 | NA | -6.366 |
| 2020-12-31 | 0.000 | NA | -2.320 |
| 2020-09-30 | 0.000 | NA | -1.452 |
| 2020-06-30 | 0.000 | NA | -1.002 |
| 2020-03-31 | 0.000 | NA | -0.943 |
CALA Price Target
For more insight on analysts targets of CALA, see our CALA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $5.00 | Average Broker Recommendation | 1.4 (Strong Buy) |
CALA Stock Price Chart Interactive Chart >
CALA Price/Volume Stats
| Current price | $0.19 | 52-week high | $2.59 |
| Prev. close | $0.22 | 52-week low | $0.15 |
| Day low | $0.19 | Volume | 1,539,200 |
| Day high | $0.22 | Avg. volume | 2,741,656 |
| 50-day MA | $0.36 | Dividend yield | N/A |
| 200-day MA | $1.07 | Market Cap | 15.19M |
Calithera Biosciences, Inc. (CALA) Company Bio
Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company was founded in 2010 and is based in South San Francisco, California.
Latest CALA News From Around the Web
Below are the latest news stories about Calithera Biosciences Inc that investors may wish to consider to help them evaluate CALA as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayGood morning, trader! |
Thinking about buying stock in SoFi Technologies, Vinco Ventures, DiDi Global, Calithera Biosciences, or ShiftPixy?NEW YORK , Jan. 20, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SOFI, BBIG, DIDI, CALA, and PIXY. Full story available on Benzinga.com |
AN2 Therapeutics Closed $80 Million Series B Financing to Advance Novel Nontuberculous Mycobacterial Lung Disease ProgramAN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet medical need, today announced several significant strides in the company's development over the past year. |
Calithera to Present at the H.C. Wainwright BioConnect Virtual ConferenceSOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the companys founder, president and chief executive officer, will present at the H.C. Wainwright BioConnect Virtual Conference. |
Great news for Calithera Biosciences, Inc. (NASDAQ:CALA): Insiders acquired stock in large numbers last yearIt is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it... |
CALA Price Returns
| 1-mo | -42.13% |
| 3-mo | -62.36% |
| 6-mo | -79.45% |
| 1-year | -91.28% |
| 3-year | -96.63% |
| 5-year | -98.82% |
| YTD | -71.44% |
| 2021 | -86.45% |
| 2020 | -14.01% |
| 2019 | 42.39% |
| 2018 | -51.98% |
| 2017 | 156.92% |
Loading social stream, please wait...